Francis D. Gibbons
AstraZeneca (United States)(US)Takeda (Japan)(JP)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Cytokine Signaling Pathways and Interactions, Mathematical Biology Tumor Growth, PI3K/AKT/mTOR signaling in cancer, Synthesis and biological activity
Most-Cited Works
- → Towards a proteome-scale map of the human protein–protein interaction network(2005)2,996 cited
- → Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia(2018)480 cited
- → Judging the Quality of Gene Expression-Based Clustering Methods Using Gene Annotation(2002)320 cited
- → Intensity-based protein identification by machine learning from a library of tandem mass spectra(2004)307 cited
- → A critical assessment of Mus musculusgene function prediction using integrated genomic evidence(2008)257 cited
- → AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia(2013)243 cited
- → Predicting Protein Complex Membership Using Probabilistic Network Reliability(2004)189 cited
- → Combining guilt-by-association and guilt-by-profiling to predict Saccharomyces cerevisiaegene function(2008)92 cited
- → Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy(2021)90 cited
- → Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC)(2019)77 cited